<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00508885</url>
  </required_header>
  <id_info>
    <org_study_id>HSC 06-0462</org_study_id>
    <nct_id>NCT00508885</nct_id>
  </id_info>
  <brief_title>The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients</brief_title>
  <official_title>The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyperphosphatemia is common in the peritoneal dialysis population. Current strategies are&#xD;
      insufficient to optimize phosphorus control. Animal studies have shown niacinamide, a form of&#xD;
      vitamin B, to reduce phosphate uptake by the rat small intestine. Our trial investigates the&#xD;
      use of niacinamide, in addition to standard phosphorus lowering strategies, to reduce plasma&#xD;
      phosphorus levels in peritoneal dialysis patients versus placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, double-blind, placebo-controlled 8-week clinical trial to&#xD;
      evaluate the efficacy of niacinamide versus placebo to reduce plasma phosphorus levels in&#xD;
      peritoneal dialysis patients. Patients on a stable regimen of phosphate binders with plasma&#xD;
      phosphorus levels &gt; 4.9 mg/dL are eligible for enrollment and randomization. The study will&#xD;
      span 8 weeks of active medication treatment. The primary end-point will be absolute change in&#xD;
      plasma phosphorus levels. Sixteen patients (8 randomized to each treatment arm) are needed to&#xD;
      detect a 1.5 mg/dL difference assuming a standard deviation of 1 and powered at 80% (alpha&#xD;
      0.05). Placebo will be packaged to resemble the study drug in all physical attributes. The&#xD;
      starting dose of niacinamide will be 250 mg twice daily to be titrated to 500 mg twice daily&#xD;
      at the end of week 2 with a final titration to 750 mg twice daily at the end of week 4.&#xD;
      Secondary end-points will include absolute change in the calcium-phosphorus product, intact&#xD;
      parathyroid hormone, hemoglobin, platelet count, total cholesterol, HDL cholesterol, and&#xD;
      percentage change in plasma phosphorus.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in plasma phosphorus after 8 weeks of niacinamide versus placebo</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in intact parathyroid hormone, calcium-phosphorus product, cholesterol profile, and percentage change in plasma phosphorus</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Hyperphosphatemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Niacinamide starting at 250 mg twice daily titrated up to 750 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacinamide</intervention_name>
    <description>Niacinamide 250 mg twice daily titrated up to 750 mg twice daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Capable of giving informed consent&#xD;
&#xD;
          -  Duration of peritoneal dialysis &gt; 3 months&#xD;
&#xD;
          -  Dose of phosphate binder(s) stable over previous 2 week period&#xD;
&#xD;
          -  Plasma phosphours &gt; 4.9 mg/dL based on most recent laboratory data within 1 month of&#xD;
             enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Known liver disease&#xD;
&#xD;
          -  Active peptic ulcer disease&#xD;
&#xD;
          -  Treatment with carbamazepine&#xD;
&#xD;
          -  Intolerance to niacinamide or niacin&#xD;
&#xD;
          -  Current medication regimen including niacin or niacinamide &gt; 100 mg daily&#xD;
&#xD;
          -  Planned or expected surgical procedure in the next 4 months&#xD;
&#xD;
          -  Patients in nursing home or extended care facilities where administration of the study&#xD;
             drug may not be appropriately given&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Daniel O Young, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University, Renal Division</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <study_first_submitted>July 26, 2007</study_first_submitted>
  <study_first_submitted_qc>July 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2007</study_first_posted>
  <last_update_submitted>July 26, 2007</last_update_submitted>
  <last_update_submitted_qc>July 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2007</last_update_posted>
  <keyword>hyperphosphatemia</keyword>
  <keyword>niacinamide</keyword>
  <keyword>ESRD</keyword>
  <keyword>peritoneal dialysis</keyword>
  <keyword>renal osteodystrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

